Tissue plasminogen activator extravasated through the cerebral vessels

Summary

Neurotoxic effects of endogenous tissue plasminogen activator (tPA) have recently been reported. Employing a rat model of thromboembolic stroke, we evaluated the extent and degree of extravasation of exogenous tPA administered for the purpose of fibrinolysis. In a thromboembolic model using Sprague-Dawley rats, focal cerebral ischemia was induced at the territory of the middle cerebral artery (MCA). Early reperfusion was induced by administering tPA (10 mg/kg) intravenously at 30 minutes after the onset of ischemia. Extravasated tPA was evaluated by immunohistochemistry, and the concentration of tPA in the brain tissue was quantified by enzyme-linked immunosorbent assay methods. The integrity of the blood-brain barrier (BBB) was examined electronmicroscopically. In a thread model of transient ischemia, reperfusion was induced without tPA adminis-tration at 30 minutes or 2 hours after the onset of ischemia, and the tPA content of the brain was quantified. In the rats with thromboembolic stroke, extravasation of tPA was observed at the territory of the MCA. Both the endogenous and exogenous tPA contents were 3.5±1.6 ng/ml of homogenized brain in saline. Electronmicroscopically, mild ischemic changes were observed, although the integrity of the BBB was preserved. In the thread model rats, the endogenous tPA contents of the ischemic hemisphere were 0.9±0.1 and 1.0±0.2 ng/ml in the 30-minute and 2-hour ischemia groups, respectively, and were significantly lower than the tPA contents in the thromboembolic stroke rats (p < 0.01). The present findings indicate that significant extravasation of exogenous tPA occurs through the cerebral vessels even though early reperfusion is induced.

Keywords

Extravasation - fibrinolysis - rat - thromboembolic stroke - tissue plasminogen activator

• References

• 1 NINDS rt-PA Stroke Study Group.. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-7.
• 2 Chen Z-L, Stickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997; 91: 917-25.
• 3 Tsirka SE, Rogove AD, Bugge T H. et al. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17: 543-52.
• 4 Wang YF, Tsirka SE, Strickland S. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nature Med 1998; 4: 228-31.
• 5 Kano T, Katayama Y, Tejima E. et al. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res 2000; 854: 245-8.
• 6 Tejima E, Katayama Y, Suzuki Y. et al. Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model. Stroke 2001; 32: 1336-40.
• 7 Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981; 46: 561-5.
• 8 Koshinaga M, Katayama Y, Fukushima M. et al. Rapid and widespread microglial activation induced by traumatic brain injury in rat brain slices. J Neurotrauma 2000; 17: 185-92.
• 9 Westergaard E, Go G, Klatzo I. et al. Increased permeability of cerebral vessels to horseradish peroxidase induced by ischemia in mongolian gerbils. Acta Neuropath 1976; 35: 307-25.
• 10 Ranby M, Nguyen G, Scarabin P Y. et al. Immunoreactivity of tissue plasminogen activator and its in- Harada et al.: Extravasation of tissue plasminogen activator 796 hibitor complexes. Thromb Haemost 1989; 61: 409-14.
• 11 Zea Longa E, Weinstein PR, Carlson S. et al. Reversible middle cerebral artery occlusion without craniectomy. Stroke 1989; 20: 84-91.
• 12 Lo EH, Bosque-Hamilton P, Meng W. Inhibition of PARP: reduction of ischemic injury and attenuation of NMDA-induced neurotransmitter dysregulation. Stroke 1998; 29: 830-6.
• 13 Alexander CM, Werb Z. Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1989; 1: 974-82.
• 14 Tsirka SE, Gualandris A, Amaral D G. et al. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-4.
• 15 Boudreau N, Sympson CJ, Werb Z. et al. Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix. Science 1995; 267: 891-3.
• 16 Coucouvanis E, Martin GR. Signals for death and survival: a two-step mechanism for cavitation in the vertebrate embryo. Cell 1995; 83: 279-87.
• 17 Flavin MP, Zhao G, Ho LT. Microglial tissue plasminogen activator (tPA) triggers neuronal apoptosis in vitro. Glia 2000; 29: 347-54.
• 18 Rogove AD, Siao C, Keyt B. et al. Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 1999; 112: 4007-16.
• 19 Nicole O, Docagne F, Margaill I. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nature Med 2001; 7: 59-64.
• 20 Broadwell RD, Balin BJ, Salcman M. Transcytotic pathway for blood-borne protein through the bloodbrain barrier. Proc Natl Acad Sci USA 1988; 85: 632-6.
• 21 Nag S, Robertson DM, Dinsdale HB. Quantitative estimate of pinocytosis in experimental acute hypertension. Acta Neuropath 1979; 46: 107-16.
• 22 Ito U, Ohno K, Yamaguchi T. et al. Effect of hypertension on blood-brain barrier change after restoration of blood flow in post-ischemic gerbil brains. Stroke 1980; 11: 606-11.
• 23 del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986; 7: 595-607.
• 24 Chan PH, Longar S, Fishman RA. Protective effects of liposome-entrapped superoxide dismutase on posttraumatic brain edema. Ann Neurol 1987; 21: 540-7.
• 25 Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev 1993; 5: 1-16.
• 26 Wang X, Lee S-R, Arai K. et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nature Med 2003; 9: 1313-7.
• 27 Yepes M, Sandkvist M, Moore E G. et al. Tissue-type plasminogen activator induces opening of the bloodbrain barrier via the LDL-receptor-related protein. J Clin Invest 2003; 112: 1533-40.
• 28 Asahi M, Asahi K, Jung J C. et al. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20: 452-7.
• 29 Rosenberg GA, Navratil M, Barone F. et al. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J Cereb Blood Flow Metab 1996; 16: 360-6.
• 30 Heo JH, Lucero J, Abumiya T. et al. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999; 19: 624-33.